



Updated Monthly

January 7, 2026

Prepared for:



THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:



Questions?

Liz Powell, Esq., MPH

lpowell@G2Gconsulting.com

www.G2Gconsulting.com

  @G2Gconsulting





GBG Report

Updated Monthly

January 7, 2026

<https://www.g2gconsulting.com/gbg-reporting-service/>

TABLE OF CONTENTS

New Opportunities

Aging.....	2
Antimicrobial Resistance	2
Artificial Intelligence & Machine Learning	3
Biomedical Research.....	3
Biotechnology and Biomanufacturing.....	4
Cancer	4
Endocrine & Metabolic Disease	4
HIV/AIDS	5
Immunology & Infectious Disease	5
NIH Common Fund.....	8
Parkinson's Disease	8
Sensory Health	9
Small Business Development	9
Therapeutics.....	10
Women's Health.....	10

Recurring Opportunities

Advanced Research Projects Agency for Health.....	11
Air Force	12
Army.....	13
BARDA	15
DARPA	15
Defense Threat Reduction Agency	16
Department of Energy	17
Navy	17
Office of the Undersecretary of Defense	17
Patient-Centered Outcomes Research Institute	17
.....	20
GBG Acronyms	20



January 15, 2026 – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 12-12:30pm EST (FREE to all) and 12:30-1:00pm (premium service private consultation for G2G and GBG clients). If you’re an affiliate of Biocom, BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Life Sciences Association, Georgia Life Sciences, IowaBio, MichBio, NCBiotech, NMBio, Ohio Life Sciences, South Dakota Biotech, VaBio, or BioWV – your membership gets you access to the [private consultation meeting](#).

Navigating Government Systems for MedTech – learn from experts with decades of experience in this five-session webinar series. Topics include securing non-dilutive government funding, shaping regulations and legislation, building relationships with decision-makers, evaluating for and obtaining FDA approval for medical innovations, ensuring quality control systems are effective, and securing reimbursement by CMS and private insurance. First session is January 27, [register now!](#)

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AGING (1)		
1.	RFI: Development of Disease Modifying Drugs to Prevent or Treat Specific Aging-Related Conditions (NIH/NIA) NOT-AG-26-001	This RFI aims to assess the early development pipeline for novel, disease-modifying drugs to prevent or treat specific aging-related conditions. NIA is seeking input from academic and industry stakeholders who have identified relevant therapeutic targets or are actively developing such drugs. NIA will use this information in its planning to enable drug development. https://grants.nih.gov/grants/guide/notice-files/NOT-AG-26-001.html	RFI	Response: 7/1/26
		ANTIMICROBIAL RESISTANCE (1)		
2.	Forecast: Clinical Research Network on Antimicrobial Resistance (NIH/NIAID) RFA-AI-27-005	The program aims to design, implement, and manage clinical research addressing key clinical questions in AMR. Research will focus on bacterial and fungal infections associated with AMR. Areas of emphasis include clinical testing of new antibiotics and other treatments such as bacteriophage therapy, methods optimizing the use of existing antibiotics, evaluating novel diagnostic tests including using diagnostics to refine treatment strategies, and mentoring the next generation of AMR clinical researchers. https://www.grants.gov/search-results-detail/361065	Total funding of \$15 million	Estimated post date: 7/1/26 Estimated proposal date: 9/29/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARTIFICIAL INTELLIGENCE & MACHINE LEARNING (1)		
3.	NIH Oligonucleotide Toxicity (OligoTox) Open Data Challenge Competition (NIH/NCATS) NOT-TR-26-006	The OligoTox Open Data Challenge is a two-phase prize competition that has the goal of creating publicly accessible, high-quality datasets from in vitro human-based systems that can lead to development of improved in silico models for predicting toxicity of an oligo based on its sequence, chemical modifications, etc. The first phase (Ideation Phase) will focus on ideation by proposing data from in vitro human-based systems that can be collected and used in predicting the toxicity of a candidate oligo therapeutic. This in vitro human-based data may be supplemented by data from in vitro and in vivo animal models to improve predictive parameters and inferences. The second Data Generation Phase will incentivize the collection, generation, and contribution of this data in creating a high-quality open dataset that can be released for public access for use in training and improving predictive models of oligo toxicity. https://ncats.nih.gov/funding/challenges	Total prizes of \$500,000	Proposal: 2/28/26 (Phase 1) Proposal: 12/31/26 (Phase 2)
		BIOMEDICAL RESEARCH (3)		
4.	Generative Optogenetics (GO) (DoD/DARPA) DARPA-PS-26-10	DARPA is soliciting innovative concepts to design a protein complex that can be expressed in vivo and responds to optical signals to synthesize a corresponding DNA or RNA sequence. This technology should enable massless transfer of genetic information to cells expressing the protein complex via a template-free mechanism that incorporates nucleotide bases in response to specific optical signals. The GO program is focused on two main Research Objectives (ROs): (1) achieving the core capability of synthesizing DNA/RNA directly in living cells using optical signals, and (2) developing error mitigation methods that ensure high-fidelity nucleic acid synthesis. https://sam.gov/workspace/contract/opp/330a7d73f8e44c2ca588697555e48829/view	Up to \$1.99 million for 1 year (Phase 1) To be negotiated, for 30 months (Phase 2)	Proposal: 2/26/26
5.	Forecast: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing (EU) HORIZON-HLTH-2026-01-TOOL-03	This topic aims to support the ongoing paradigm shift in biomedical research and safety assessment of chemical compounds by fully integrating NAMs across the entire research and regulatory spectrum, from basic discovery phase to clinical application, and regulatory testing of medicinal products and medical devices, and/or industrial and environmental chemicals. https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2026-01-TOOL-03	Total funding of €49 million	Proposal: 4/16/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOMEDICAL RESEARCH		
6.	Bio in Space Innovation Challenge (TechConnect)	TechConnect seeks breakthrough technologies that leverage space and microgravity to advance development and commercialization in biotechnology, human health, and advanced biomaterials. Areas of Interest: Microgravity for Drug Development; Microgravity for Regenerative Medicine; Disease Modeling and Space Radiation; Advanced Biomaterials & Medical Devices; Human Health in Space; and Automation and AI Solutions. https://www.techconnectworld.com/World2026/Bio-In-Space-Challenge/	Pitch opportunity; total prizes of \$50,000	Proposal: 2/5/26 Presentations 3/10-12/26
		BIOTECHNOLOGY AND BIOMANUFACTURING (1)		
7.	Single Blood Donor Collection and Storage Bags Manufactured in Continental United States (CONUS) (MTEC) MTEC-26-01-BloodBag	In recent years, there has been a shortage of much needed blood storage bags, which is acute within the DoD system where there is a requirement for individually wrapped blood bags for use in far forward situations. The U.S. Government is looking for solutions to stand up CONUS manufacturing capabilities to ensure rapid scalable blood bag production in the event of need. https://mtec-sc.org/solicitations/bloodbag	Up to \$3 million, for up to 1 year	Proposal: 1/30/26
		CANCER (1)		
8.	Gateway for Cancer Research Grant Programs (Gateway)	Gateway exclusively funds Phase I and Phase II research trials, which often mark the first-in-human study of promising new cancer drugs and therapies. This includes rare cancers for which funding is scarce as well as some of the most prevalent cancers affecting men, women and children today. https://gatewaycr.smapply.org/prog/gfcr_all_grant_programs_-_v122023/	Up to \$1.5 million, for up to 5 years	Letter of intent: 5/15/26
		ENDOCRINE & METABOLIC DISEASE (3)		
9.	Identifying the Effects of GLP-1 Medications Among Individuals with Cardiovascular, Kidney and Metabolic (CKM) Disease (AHA)	We invite proposals for a research project focused on evaluating the effects of GLP-1 and/or GIP agonists among individuals with cardiovascular, kidney, and metabolic disease (CKM) and/or obesity. https://professional.heart.org/en/research-programs/aha-funding-opportunities/glp1-medications-in-people-with-ckm-disease	\$300,000 for 2 years	Letter of intent: 1/19/26 Invited proposal: 3/23/26
10.	In vitro Disease Modeling: Type I Diabetes-on-a-Chip Platforms for Translational Research (Breakthrough T1D)	This RFA supports advancement of cutting-edge organoid- and organ on a chip-based disease models of T1D. It aims to validate and refine existing human-relevant in vitro models of T1D as tools for evaluation of pharmacological and genetic interventions with the goal of accelerating translation to clinical studies. https://www.breakthrought1d.org/wp-content/uploads/2025/12/RFA_Organ-on-a-chip_Call-Document.pdf	Up to \$300,000 for 1 year	Letter of intent: 1/28/26 Invited proposal: 3/11/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ENDOCRINE & METABOLIC DISEASE		
11.	Translational Strategies to Define, Enhance, and Monitor Vascularization for Durable Islet Replacement Therapies (Breakthrough T1D)	<p>This RFA supports translational research that advances the clinical application of vascularization- and engraftment-focused strategies for islet replacement therapy in type 1 diabetes (T1D). Funded projects must address at least one of the following areas: 1) define vascular features that correlate with or predict graft function and long-term durability; 2) advance strategies to enhance vascular integration, perfusion and graft resilience at extrahepatic transplant sites; or 3) advance non-invasive technologies to monitor neovascularization, perfusion, vascular stability, and oxygenation in vivo.</p> <p>https://www.breakthrought1d.org/wp-content/uploads/2025/12/RFA_Vascularization_Call-Document.pdf</p>	Up to \$900,000 for up to 3 years	Letter of intent: 1/28/26 Invited proposal: 3/11/26
		HIV/AIDS (1)		
12.	Forecast: Centers for Structural Biology of HIV and other Infectious Diseases (NIH/NIAID) RFA-AI-27-009	<p>This solicitation will support multidisciplinary groups of scientists to determine the 3-dimensional structures of molecules and molecular complexes involved in priority infectious diseases. The effort focuses on exploring biomolecular complexes that can be targeted to make new medicines and tests to prevent or treat infections and improve human health. The centers will drive cutting-edge research and development of structural biology technologies, including high-resolution 3D structural analyses, computational molecular dynamics, functional and mechanistic characterization at the molecular and cellular level, visualization at the atomic level of molecular complexes in cells and tissues, and advanced structure-guided design of molecules to combat infectious diseases.</p> <p>https://www.grants.gov/search-results-detail/361050</p>	TBD	Estimated post date: 8/18/26 Estimated proposal date: 12/18/26
		IMMUNOLOGY & INFECTIOUS DISEASE (9)		
13.	Forecast: Increasing awareness and knowledge of Alpha-gal Syndrome in the United States (CDC/NCEZID) CDC-RFA-CK-26-0193	<p>This NOFO seeks to improve AGS surveillance, patient care, and public awareness and understanding. The NOFO strategies are to 1) SHARE - Formation of an association of AGS professionals to disseminate latest knowledge of AGS among stakeholders, including public health agencies, academic researchers, and advocacy groups, in order to improve patient care for AGS and the public health response. 2) EDUCATE - Create AGS communications targeted at the general public, AGS patients, or persons at higher risk for tick encounters. Create communications targeted at healthcare providers including educational resources and training. 3) TRACK - Conduct active or enhances public health surveillance for AGS.</p> <p>https://www.grants.gov/search-results-detail/360958</p>	Up to \$1 million	Estimated post date: 2/28/26 Estimated proposal date: 5/1/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
14.	Forecast: Reducing the burden of parasitic infections in the United States through evidence-based prevention and control activities. (CDC/NCEZID) CDC-RFA-CK-26-0221	Reducing the burden of parasitic infections in the United States through evidence-based prevention and control activities. https://www.grants.gov/search-results-detail/360957	Up to \$1.25 million	Estimated post date: 4/6/26 Estimated proposal date: 6/5/26
15.	Forecast: Advancing outbreak detection, notification, and response capacity through 7-1-7 implementation in partner countries (CDC/GHC) CDC-RFA-JG-26-0214	Building on previous outbreak experience and other international health emergencies, this NOFO advances American interests by reinforcing systems that protect both the United States and recipient nations. Activities focus on improving early detection of biological threats, timely notification across sectors and borders, and effective response to contain outbreaks before they spread. https://www.grants.gov/search-results-detail/361093	TBD	Estimated post date: 2/10/26 Estimated proposal date: 4/11/26
16.	Forecast: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions (EU) HORIZON-HLTH-2026-01-DISEASE-03	Microbial infections can lead to long-lasting consequences on patients' quality of life, leading to long-term conditions characterised by persistent inflammation, organ damage, and impaired functional capacity, which pose a growing public health and economic challenge. These conditions are insufficiently understood, underdiagnosed, and lack effective treatments. Advancing research into their prevention, treatment and management is essential to improving patient outcomes, reducing healthcare burdens, and strengthening workforce productivity. https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2026-01-DISEASE-03	Total funding of €39.3 million	Proposal: 4/16/26
17.	Forecast: Development of novel vaccines for viral pathogens with epidemic potential (EU) HORIZON-HLTH-2026-01-DISEASE-04	Applicants should explicitly state in their proposal which of the following viruses is targeted and the proposed work should address only this specific virus. The proposed work should aim to advance the development of existing prophylactic and therapeutic vaccine candidates targeting exclusively one of the following viruses: Junin mammarenavirus; Lassa mammarenavirus; Andes virus; Hantaan virus; Sin Nombre virus; Hendra virus; Enterovirus D68; Venezuelan equine encephalitis virus. https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2026-01-DISEASE-04	Total funding of €44.2 million	Proposal: 4/16/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
18.	Forecast: Tuberculosis Research Advancement Centers (TRACs) (NIH/NIAID) RFA-AI-27-016	TRACs are designed to advance TB research by providing scientific leadership and administrative support to mentor or train early career investigators and/or those new to TB research. This initiative will also provide short term funding for TB-specific pilot awards and high impact collaborative studies with other TRACs, as well as resources and training for basic and clinical research. https://www.grants.gov/search-results-detail/361026	TBD	Estimated post date: 4/3/26 Estimated proposal date: 6/2/26
19.	Assay Development for Superior Understanding of Response and Efficacy (ASSURE) (BARDA/RRPV) RRPV 26-07-ASSURE	The ASSURE program aims to develop innovative, multiplexed, high-throughput, scalable and sample sparing assays that provide comprehensive evaluation of an individual's immune status as a response to either infection or vaccination. This program seeks to de-risk the development of novel assay platform technologies with the ultimate goal of establishing new, qualified assays primarily for BARDA and vaccine developers to comprehensively assess the immune response and status elicited by vaccines and/or infection due to CBRN threats, pandemic influenza, or other emerging infectious diseases. Some of these assays may lead to support of new correlates of protection. https://www.rpv.org/uncategorized/assay-development-for-superior-understanding-of-response-and-efficacy-assure/	Dependent upon proposal and available funds	Proposal: 2/24/26
20.	RFI: New Vaccine Platforms (BARDA/RRPV)	The objective of this RFI is to solicit feedback from industry, academia, and other stakeholders to assist BARDA in identifying, and understand the development maturity of, vaccine platform technologies that (1) are safe and effective across a broad range of different known infectious disease threats and (2) can enable efficient development timelines in response to emerging infectious disease threats. https://www.rpv.org/solicitation/request-for-information/new-vaccine-platforms/	N/A	Response: 1/30/26
21.	Forecast: SMART Antiviral Prize (BARDA/VITAL)	The goal of this competition is to advance the development of novel antivirals that strengthen the therapeutic pipeline and address gaps in strategic preparedness in partnership with innovators offering creative solutions. The SMART Antiviral Prize focuses on supporting the development of antivirals with broad-spectrum activity against members of the Togaviridae and/or Flaviviridae families. There are currently no FDA-approved broad-spectrum antivirals for any viruses within these families—which include dengue, Zika, West Nile, and Chikungunya. https://vitalhubhealth.com/SMARTantiviral/	TBD	Launch event: 1/7/26 Deadlines TBD



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NIH COMMON FUND (4)		
22.	Forecast: NIH Director's Pioneer Award Program (DP1 Clinical Trial Optional) (NIH Common Fund) RFA-RM-26-001	The NIH Director's Pioneer Award supports individual scientists of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator's research program or elsewhere. Applications in any area within the biomedical sciences are welcome. https://www.grants.gov/search-results-detail/360986	Up to \$700,000	Estimated post date: 7/9/26 Estimated proposal date: 9/9/26
23.	Forecast: NIH Director's New Innovator Award Program (DP2 Clinical Trial Optional) (NIH Common Fund) RFA-RM-26-002	The NIH Director's New Innovator Award supports early stage investigators of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. Applications in any area within the biomedical sciences are welcome. https://www.grants.gov/search-results-detail/360987	Up to \$475,000	Estimated post date: 6/19/26 Estimated proposal date: 8/19/26
24.	Forecast: NIH Director's Transformative Research Awards (R01 Clinical Trial Optional) (NIH Common Fund) RFA-RM-26-003	The NIH Director's Transformative Research Award supports individual scientists or groups of scientists proposing bold, groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. Applications in any area within the biomedical sciences are welcome. No preliminary data are required. https://www.grants.gov/search-results-detail/361084	Total funding of \$8 million	Estimated post date: 7/3/26 Estimated proposal date: 8/30/26
25.	Forecast: NIH Director's Early Independence Awards (DP5 Clinical Trial Optional) (NIH Common Fund) RFA-RM-26-004	The NIH Director's Early Independence Award supports rigorous and promising investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. Applications in any area within the biomedical sciences are welcome. https://www.grants.gov/search-results-detail/360988	Up to \$350,000	Estimated post date: 7/4/26 Estimated proposal date: 9/4/26
		PARKINSON'S DISEASE (1)		
26.	Parkinson's Disease Therapeutics Pipeline Program (MJFF)	This program advances therapeutic development through pre-clinical and/or into clinical testing of approaches addressing unmet needs of people with PD with clear potential to prevent, stop, or delay disease progression or to reduce the burden of daily symptoms. A unique goal of this program is to promote clearer paths to commercialization and market access by the PD community. https://www.michaeljfox.org/grant/parkinsons-disease-therapeutics-pipeline-program	Up to \$2 million, for up to 3 years Dependent upon award mechanism	Proposal: 2/22/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SENSORY HEALTH (1)		
27.	Forecast: Addressing Sensory Health Needs Across the Lifespan PCORI Funding Announcement -- Cycle 2 2026 (PCORI)	<p>PCORI's description of sensory health includes conditions affecting one or more of the body's sensory systems, such as visual, auditory, olfactory, touch, taste, proprioceptive, vestibular and interoceptive systems. PCORI is particularly interested in submissions that address the following Special Areas of Emphasis: Increasing screening and early detection for people with sensory health conditions; Improving treatment and care coordination for people with sensory health conditions; and Enhancing support services to improve mental health and address stigma experienced by individuals with sensory health conditions, their families and their care partners.</p> <p>https://www.pcori.org/funding-opportunities/announcement/addressing-sensory-health-needs-across-lifespan-pcori-funding-announcement-cycle-2-2026</p>	Up to \$12 million, for up to 5 years	<p>System opens: 4/1/26</p> <p>Letter of intent: 4/28/26</p> <p>Proposal: 9/1/26</p>
		SMALL BUSINESS DEVELOPMENT (2)		
28.	<p>DoD SBIR 25.4 Release 12 (DoD/CBD)</p> <p>DoD SBIR 2025.4</p>	<p>Topics include: Shelf-Stable Nucleic Acid Synthesis Reagents for Field-Deployable Diagnostics; OPEN TOPIC - Expeditionary Biologics-on-Demand (BOND); Microphysiological systems to Assess Pretreatment Immunogenicity and Efficacy (MAGPIE); Complex Geometries for Extended Wear Respirators Towards Regenerable Particulate Matter Protection; Novel Sampling Tickets for Surface Enhanced Raman Spectroscopy (SERS) of Chemical and Biological (CB) Threat Materials; Unbiased Behavioral Discovery Platforms; and Novel Technologies for CWMD and Related Threats.</p> <p>https://www.dodsbirsttr.mil/topics-app/</p>	<p>Up to \$209,575, for up to 6 months (Phase I)</p> <p>Up to \$1.397 million, for up to 2 years (D2P2)</p>	Proposal: 2/4/26
29.	<p>RFI: Foundational Innovation and RAPID Engagement (FIRE) (FDA)</p> <p>FDA-26-132067</p>	<p>The FDA is seeking information from Venture Capital (VC) firms regarding their interest in and requirements for a novel contract vehicle that would enable portfolio companies to compete directly for FDA contracts and task orders. The FDA recognizes that many breakthrough technologies and innovative solutions relevant to our public health mission are being developed by companies within VC portfolios. These companies often possess cutting-edge capabilities in areas such as artificial intelligence, biotechnology, medical devices, and regulatory technology that could significantly benefit FDA operations and the broader public health ecosystem.</p> <p>https://sam.gov/workspace/contract/opp/b9feb7a7a1ee45d0ac96fbb5ea1628b5/view</p>	RFI	Response: 1/18/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		THERAPEUTICS (2)		
30.	RFI: Call for Input into NIH's Best Pharmaceuticals for Children Act (BPCA) Priorities for 2026 and Beyond (NIH/NICHD) NOT-HD-25-004	The NICHD invites all stakeholders to engage and provide expert opinions into two areas related to the Best Pharmaceuticals for Children Act (BPCA) NIH 409I Clinical Program: To submit nominations for research to be prioritized in the development of the Best Pharmaceuticals for Children Act (BPCA) Program's 2026 Priority List of Needs in Pediatric Therapeutics; and To provide expert review of resources to be added to the existing BPCA Framework to support Pediatric Drug Development. The NICHD is gathering nominations for drugs and therapeutic areas that require further study in children. https://grants.nih.gov/grants/guide/notice-files/NOT-HD-25-004.html	RFI	Response: 1/30/26
31.	iNext Pitching Competition (Sanofi)	iNext is a pitching competition designed to spark transformational "moon-shot" ideas. Sanofi invites innovative Startups and Academic Labs from both North America and Europe to submit groundbreaking proposals, in the fields of either (1) Next-Gen approaches to counter aging related cellular and tissue dysfunction and/or (2) paradigm shifting strategies for targeted delivery of large molecules and nucleic acids. https://sanofi.agorize.com/en/challenges/inext-2026?lang=en	Up to \$500,000, for 18 months	Pre-proposal: 1/31/26 Invited proposal: 3/31/26
		WOMEN'S HEALTH (1)		
32.	Forecast: Women's Initiative for Screening and Health (WISH) (HHS/HRSA) HRSA-26-016	The purpose of Women's Initiative for Screening and Health (WISH) is to improve women's health across the lifespan by increasing access to and availability of preventive health services. Through a multidisciplinary coalition of healthcare providers, academic institutions, and patient-centered organizations, WISH drives a comprehensive strategy to: (1) review and recommend evidence-based updates to the HRSA-supported women's preventive service guidelines (Guidelines), (2) raise awareness and knowledge of the (Guidelines), and (3) increase adoption and use of the Guidelines in clinical practice. https://www.grants.gov/search-results-detail/360992	Up to \$1 million	Estimated post date: 2/2/26 Estimated proposal date: 4/4/26





Recurring Opportunities

January 7, 2026

<https://www.g2gconsulting.com/gbg-reporting-service/>

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (4)		
33.	Resilient Systems Office (RSO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-103	RSO is interested in innovations that take a systems level approach in areas including, but not limited to, systems biology, data systems, biophysical systems, health IT systems, sociotechnical systems, health-related systems engineering, and other systems with the potential to improve health outcomes. https://sam.gov/workspace/contract/opp/36eb58892e1f49f897c81d87ff7a95fe/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
34.	Health Science Futures (HSF) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-104	HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support: Breakthrough Technologies; Transformative Tools; and Platform Systems. https://sam.gov/workspace/contract/opp/29c3ac2ea6754d1f897f9c71204c0eea/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
35.	Scalable Solutions Office (SSO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-105	ARPA-H SSO seeks solutions to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise by developing location-specific interventions, telemedicine solutions, and mobile health clinics. Solutions should focus on rapid innovation and the use of partnerships, also flexible distribution networks and streamlined manufacturing processes. SSO interest areas include: Advanced Technologies for Medical Product and Capability Distribution; and Biomanufacturing Innovations. https://sam.gov/workspace/contract/opp/c79dfo57a7e44d2cb3072e4ce3307422/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
36.	Proactive Health Office (PHO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-106	The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Interest areas include: Novel prevention, detection and prophylactic treatment methods for disease; Population-level approaches to increase the adoption of prevention and wellness behaviors; and System innovation for the delivery of proactive health outcomes. https://sam.gov/workspace/contract/opp/a5b72db5139040f8b2a1dcc2d2c96733/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE (4)		
37.	Continuing Human Enabling, Enhancing, Restoring and Sustaining (CHEERS) FA238424S2233	CHEERS MAA is intended to provide a comprehensive strategy for AFRL/RH and USAFSAM's range of S&T, allowing for progression from basic research to technology maturation and transition. Areas of interest include: Aerospace Medicine and Physiology; Public Health and Preventative Medicine; Occupational Medicine and Bioenvironmental Engineering; and En Route Care/Expeditionary Medicine/Prolonged Field Care. https://sam.gov/opp/4caa8d320fb24050b389fe721296a13d/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis
38.	AFRL/RX Functional Materials Open BAA FA8650-22-S-5002	The Functional Material Open BAA seeks to exploit innovative functional materials that enable new warfighting capabilities, significantly improve the effectiveness of warfighters and their current and future systems and solve urgent operational needs. The Biomaterials Materials and Processes (BM&P) Research area seeks to accelerate materials development, protect assets from the environment, and enable airman performance. This research area harnesses materials and processes competencies in soft matter materials characterization, molecular and synthetic biology, microbiology, biochemistry, bioinformatics, machine learning, multiscale modeling, bioelectronics, bio- functionalization, and biological engineering to create materials not easily achievable through traditional chemical synthesis or additive manufacturing. https://sam.gov/opp/2fadbd41c2700409c993a8c308c6f5120/view	Dependent upon proposal and award mechanism	White paper: 10/28/28
39.	Research Interests of the Air Force Office of Scientific Research FA9550-25-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. The Chemistry and Biological Sciences Team is responsible for research activities in chemistry and biological sciences. The focus is on complex materials, microsystems and structures and well as systems of a biological nature by incorporating hierarchical design of mechanical and functional properties from the nanoscale through the mesoscale, ultimately leading to controlled well- understood chemistry/biochemistry, and material or structural behavior capable of dynamic functionality and/or performance characteristics to enhance mission versatility. https://www.grants.gov/search-results-detail/359050	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
40.	Research Interests of the United States Air Force Academy USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/search-results-detail/330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY (10)		
41.	The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Broad Other Transaction Authority Announcement (BOTAA) BOTAA-24-01	JPEO-CBRND is interested in efforts directed toward the development of enabling technologies that speed up the advanced development process. Areas of interest include: Software and Artificial Intelligence (AI), wearable sensors, threat detection, biothreat containment and aeromedical evaluation. https://sam.gov/opp/2d04622b25364669857a6a61c576ade9/view	Dependent upon proposal	Preproposals accepted through 2/7/29
42.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/f2d01f5a6c444e32af543e9519a0805f/view	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
43.	USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; and Military Operational Medicine. https://www.grants.gov/search-results-detail/343725	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
44.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; prolonged field care (PFC); human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/search-results-detail/349586	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
45.	Medical CDID BAA MED CDID	MED CDID invites innovative proposals that allow future Army medical units to efficiently and effectively clear the battlefield (evacuation of wounded, ill, and injured), maximize return to duty, and overcome contested logistics (medical resupply). https://vulcan-sof.com/login/ng2/submission?collectionUuid=5417cc3c-2b60-446a-addf-cobe38cd0b1	Dependent upon proposal	White papers accepted through 12/31/2030



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
46.	Army Research Office Laboratory Broad Agency Announcement for Foundational Research W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; the full list of research topics is available . https://sam.gov/opp/7560e5d4024b4e94ad3eab6180cfcc36/view	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27
47.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://sam.gov/opp/ee8d9eeec4f94269b6e1ac16b09d9417/view	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required
48.	Army Applications Lab BAA for Disruptive Applications W911NF-24-S-0008	AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch. https://sam.gov/opp/3f8ec6d36d584ca28364a2f8a10255b7/view	Dependent upon proposal	Proposals accepted through 4/4/29 Pre-proposal is required
49.	Basic and Applied Research at the US Army Combat Capabilities Development Command - Soldier Center W911QY-25-R-0023	The Soldier Center is seeking solutions in the following scientific and technical areas: Combat Feeding & Equipment; Soldier Protection & Survivability; Modeling & Simulation; Human Performance & Biomechanics; Expeditionary Maneuver Support; Aerial Delivery; and Simulation & Training Technology. https://sam.gov/opp/e85e373d22ef47018b0336fc6a258002/view	Dependent upon proposal	Concept papers accepted on a rolling basis until 2/27/30
50.	BAA for Chemical, Biological, Radiological, Nuclear, and Explosive Defense Efforts W911SR-24-R-DEVB	DEVCOM CBC's mission is to provide innovative chemical, biological, radiological, nuclear and explosive (CBRNE) defense capabilities to enable the Joint Warfighters' dominance on the battlefield and interagency defense of the homeland. Mission areas include: Sensor technologies and biomaterials; Biological point detection; Chemical point detection; Early warning and detection; Collective protection; Respiratory protection; Decontamination; CBRN countermeasures; and Chemical biological advanced materials and manufacturing science. https://sam.gov/opp/fca6a4b42ff94fd5892fdae9799941f/view	Dependent upon proposal and award mechanism	Preproposals accepted through 8/20/29



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		<u>BARDA (2)</u>		
51.	BARDA Broad Agency Announcement BAA-23-100-SOL-00004	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; Flexible and Strategic Therapeutics (FASTx). https://sam.gov/opp/d832248e72e14c3c8cee96ee3c8b2170/view	Dependent upon proposal	Proposal: 9/25/28
52.	BARDA DRIVe EZ-BAA DRIVeEZBAA22100SOL00003	All AOIs are currently closed. No initial awards will be executed. Eligible +Phase submissions will still be accepted and reviewed in accordance the process outlined the EZBAA and corresponding AOI. https://sam.gov/opp/6684d4a2734047d58d6cbf7e50bdd00a/view	Up to \$750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		<u>DARPA (3)</u>		
53.	Expedited Research Innovation System (ERIS) DARPA-PS-25-05	DARPA seeks to obtain solutions or capabilities that deliver breakthrough technological advancements that are new as of the date of submission; or technologies, processes, research or methods. Topics include: Advanced technologies for defense against potential chemical and biological threats; Advanced technologies for the improved resilience of US operations throughout the prepare, deployment, execute, and return cycle; and Development of groundbreaking methods and metrology for complex, emergent, and adaptive systems, going beyond the limitations of current reductive scientific methods. https://sam.gov/workspace/contract/opp/fabda3a3d150457d97068977672ec750/view	Dependent upon proposal and award mechanism	Proposal: 5/30/26
54.	Biological Technologies BAA HR001124S0034	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: AI/ML; Combat Casualty Care; Human Performance; Materials, Sensors, Processing; Agricultural and Environmental; Security, Safety, and Surveillance; and Biomedical and Biodefense. https://sam.gov/workspace/contract/opp/8d403582edfd409795560247e8d229b7/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 9/30/26
55.	Defense Sciences Office, Office-wide HR001125S0013	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Materials, Manufacturing, & Structures; Sensing and Measurement; Math, Computation, and Processing; Complex, Dynamic, and Intelligent Systems. https://sam.gov/opp/c3f0bedbf22c4e2daf5bbo713f4ce4a/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 6/2/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEFENSE THREAT REDUCTION AGENCY (4)		
56.	Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E : <ul style="list-style-type: none"> • Understand current and emerging WMD situations, threats, and capabilities • Enable effective and integrated WMD deterrence • Control, disable, and defeat current and emerging WMD threats • Protect the force and mitigate crises from WMD • Enable cross-cutting capabilities https://sam.gov/workspace/contract/opp/d5bcd60592c84adf908c5c1ca747bc4e/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27
57.	Biological Threat Reduction with Global Partners Broad Agency Announcement (BAA) HDTRA1-24-S-0002	BTRP supports international health security efforts to address diseases caused by U.S. Biological Select Agents, pathogens of pandemic potential, and emerging infectious diseases. BTRP achieves its mission through collaboration with partner countries and the international community to minimize the threat of deliberate, accidental, and natural infectious disease outbreaks through enhanced detection, diagnosis, and reporting capabilities and biosecurity and biosafety measures. https://www.grants.gov/search-results-detail/353860	Dependent upon proposal and award mechanism	Proposal: 4/28/29
58.	FY25-29 Strategic Trends Research Initiative Broad Agency Announcement HDTRA1-24-S-0003	SI-ST's research explores a range of challenges related to nuclear, chemical, and biological weapons. The three WMD-relevant Research Thrust Areas are: strategic international dialogues, analytical studies, and emerging CWMD researcher projects. An area of general interest is: Future trends related to biological warfare, biodefense, biosecurity, and bio preparedness. https://sam.gov/opp/7a98bf70ac2a49c8b8eod71abbc93750/view	Dependent upon proposal and award mechanism`	White papers accepted on a rolling basis through 8/1/29
59.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-25-S-0001	Fundamental research efforts enable capabilities such as development of improved detection devices for traditional and nontraditional chemical agents; development of diagnostics for existing and emerging infectious disease threats; increasing knowledge and improved capabilities for development of new or improved medical and material countermeasures to CB threats for both pre- and post-exposure scenarios; enhanced personal protection against, modeling of, prevention of, or decontamination of CB threats; and providing effective elimination strategies via non-kinetic approaches for threat agent destruction, neutralization and/or sequestration. https://www.grants.gov/search-results-detail/356612	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2034



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEPARTMENT OF ENERGY (1)		
60.	FY 2026 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0003600	SC accomplishes its mission and advances national goals by supporting: The frontiers of science—exploring nature’s mysteries from the study of fundamental subatomic particles, atoms, and molecules that are the building blocks of the materials of our universe and everything in it to the DNA, proteins, and cells that are the building blocks of life. Each of the programs in SC supports research probing the most fundamental disciplinary questions. https://www.grants.gov/search-results-detail/360678	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/26
		NAVY (2)		
61.	FY25 Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N0001425SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://sam.gov/workspace/contract/opp/oefe2fde0926428f8ecc073fc7b5d9/view	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/26
62.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-24-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/workspace/contract/opp/f85a428ac9ac46c4a3278e11394c18d9/view	Dependent upon proposal and award mechanism	White papers accepted through 3/31/26
		OFFICE OF THE UNDERSECRETARY OF DEFENSE (1)		
63.	OUSD(R&E) Seeks Advanced Manufacturing, Prototypes and Materials (AMPAM) HQ003425BOTA1	OUSD(R&E)’s goal is to foster increased collaboration and partnership between Government and Industry to identify, develop, and mature new or improved manufacturing and repair processes and bridge the gap between discovery and implementation of new capabilities for the warfighter. Examples may include Bio-manufacturing of medical related material and Bio-manufacturing of materials or products in the supply chain. https://sam.gov/opp/64a31b87112843b58dfb13f37bfa3df1/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis through 10/2/27
		PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE (7)		
64.	Engagement Award: Capacity Building – Spring 2026 Cycle	The Engagement Award: Capacity Building opportunity funds projects that build communities prepared to participate in PCOR/CER. These awards support organizations with strong ties to patients, caregivers, clinicians, and other stakeholders who have a connection to a research focus area and seek to better equip stakeholders to engage as partners in PCOR/CER. https://www.pcori.org/funding-opportunities/announcement/engagement-award-capacity-building-spring-2026-cycle	Up to \$300,000, for up to 2 years	System opens: 1/21/26 Letter of intent: 3/30/26 Proposal: 7/13/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE		
65.	Engagement Award: Dissemination Initiative -- Spring 2026 Cycle	<p>The Engagement Award: Dissemination Initiative funding opportunity aims to support projects that help organizations and communities plan for or actively bring pertinent PCORI-funded research findings to their specific audiences, including relevant patients, clinicians, communities, and others, in ways that will command their attention and interest and encourage use of this information in their healthcare decision making.</p> <p>https://www.pcori.org/funding-opportunities/announcement/engagement-award-dissemination-initiative-spring-2026-cycle</p>	Up to \$300,000, for up to 2 years	<p>System opens: 1/21/26</p> <p>Letter of intent: 3/30/26</p> <p>Proposal: 7/13/26</p>
66.	Engagement Award: Stakeholder Convening Support -- Spring 2026 Cycle	<p>The Engagement Award: Stakeholder Convening Support funding opportunity provides support to organizations and communities to hold multi-stakeholder convenings, meetings, and conferences that include a combination of patients, caregivers, researchers, clinicians, purchasers, payers, health system leaders, and/or other stakeholders. Convenings should be designed with the active collaboration and partnership of patients, community groups, and/or other stakeholder organizations.</p> <p>https://www.pcori.org/funding-opportunities/announcement/engagement-award-convening-support-spring-2026-cycle</p>	Up to \$125,000, for up to 1 year	<p>System opens: 1/21/26</p> <p>Letter of intent: 3/30/26</p> <p>Proposal: 7/13/26</p>
67.	Forecast: Advancing the Science of Engagement in Research PCORI Funding Announcement -- Cycle 2 2026	<p>This PFA will fund studies that build an evidence base on engagement in research, including: Measures to capture structure/context, process, and outcomes of engagement in research; Techniques that lead to effective engagement in research; and How effective engagement techniques should be modified and resourced for different contexts, settings, and communities. It will solicit applications that focus on: Development and validation of measures to capture structure/context, process and outcomes of engagement, for both stakeholders and investigators; and Development and/or testing of engagement methods to generate evidence on the most effective approaches for engagement in research and how effectiveness varies by context.</p> <p>https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-research-pcori-funding-announcement-cycle-2-2026</p>	Up to \$1.5 million, for up to 3 years	<p>System opens: 4/1/26</p> <p>Letter of intent: 4/28/26</p> <p>Proposal: 9/1/26</p>



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE		
68.	Forecast: Broad Pragmatic Studies Funding Announcement - Cycle 2 2026	<p>PCORI seeks to fund patient-centered CER comparing two or more alternatives, each of which has established efficacy and/or is in widespread use. PCORI is interested in research that fills pertinent evidence gaps representing decisional dilemmas for patients, caregivers, clinicians, policymakers and other healthcare system stakeholders, with a goal of generating evidence that helps patients and members of the broader healthcare community make informed decisions about their health care and health outcomes. Applicants for the 2026 BPS PFA may select up to three of PCORI's Topic Themes; or "Other." Cycle 1 SAEs include: Addressing Obesity; Treatments and Strategies To Address Menopausal Symptoms; and Improving Care Delivery for Individuals With Intellectual and Developmental Disabilities (IDD).</p> <p>https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-pcori-funding-announcement-cycle-2-2026</p>	Up to \$12 million, for up to 5 years Dependent upon award mechanism	<p>System opens: 4/1/26</p> <p>Letter of intent: 4/28/26</p> <p>Proposal: 9/1/26</p>
69.	Forecast: Improving Methods for Conducting Patient-Centered Comparative Clinical Effectiveness Research PCORI Funding Announcement -- Cycle 2 2026	<p>PCORI seeks to fund projects that address important methodological gaps and lead to improvements in the strength and quality of evidence generated by CER studies. For this PFA, PCORI has identified the following areas as programmatic priorities: Methods to Improve the Use of AI and ML in CER; Methods to Improve Study Design; Methods to Support Data Research Networks; Methods Related to Ethical and Human Subjects Protections Issues in CER.</p> <p>https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-comparative-clinical-effectiveness-research-pcori-funding-announcement-cycle-2-2026</p>	Up to \$750,000, for up to 3 years	<p>System opens: 4/1/26</p> <p>Letter of intent: 4/28/26</p> <p>Proposal: 9/1/26</p>
70.	Forecast: Phased Large Awards for Comparative Effectiveness Research -- Cycle 2 2026	<p>PCORI is interested in research that aims to fill pertinent evidence gaps representing decisional dilemmas for patients, caregivers, clinicians, policymakers and other healthcare system stakeholders, with a goal of generating evidence that helps patients and members of the broader health and healthcare community make informed decisions about their health care and health outcomes. Applicants to the Cycle 1 2026 PLACER PFA may select up to three Topic Themes; or Other.</p> <p>https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-pcori-funding-announcement-cycle-2-2026</p>	Up to \$22 million, for up to 6.5 years	<p>System opens: 4/1/26</p> <p>Letter of intent: 4/28/26</p> <p>Proposal: 9/1/26</p>





Terms

AoI: Area of Interest
BAA: Broad Agency Announcement
FOA: Funding Opportunity Announcement
IC: NIH Institutes and Centers
NOFO: Notice of Funding Opportunity
NOSI: Notice of Special Interest
PI: Principal Investigator
RFI: Request for Information
RFP: Request for Proposal
SBIR: Small Business Innovation Research
SDOH: Social Determinants of Health
STTR: Small Business Technology Transfer
TRL: Technology Readiness Level

Agencies

ARPA-H: Advanced Research Projects Agency for Health
ASPR: Administration for Strategic Preparedness and Response
BARDA: Biomedical Advanced Research and Development Authority
CDC: Centers for Disease Control and Prevention
CDMRP: Congressionally Directed Medical Research Programs
DARPA: Defense Advanced Research Projects Agency
DHA: Defense Health Agency
DoD: Department of Defense
FDA: U.S. Food and Drug Administration
MTEC: Medical Technology Enterprise Consortium
NIH: National Institutes of Health
NSF: National Science Foundation
PCORI: Patient-Centered Outcomes Research Institute
USAMRDC: U.S. Army Medical Research and Development Command
USAMRIID: U.S. Army Medical Research Institute of Infectious Diseases
USSOCOM: United States Special Operations Command

GBG Acronyms

Updated Monthly

January 7, 2026

<https://www.g2gconsulting.com/gbg-reporting-service/>

NIH Institutes and Centers

CC: NIH Clinical Center
CIT: NIH Center for Information Technology
CSR: NIH Center for Scientific Review
FIC: Fogarty International Center
NCATS: National Center for Advancing Translational Sciences
NCCIH: National Center for Complementary and Integrative Health
NCI: National Cancer Institute
NEI: National Eye Institute
NHGRI: National Human Genome Research Institute
NHLBI: National Heart, Lung, and Blood Institute
NIA: National Institute on Aging
NIAAA: National Institute on Alcohol Abuse and Alcoholism
NIAID: National Institute of Allergy and Infectious Diseases
NIAMS: National Institute of Arthritis & Musculoskeletal & Skin Diseases
NIBIB: National Institute of Biomedical Imaging and Bioengineering
NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development
NIDA: National Institute on Drug Abuse
NIDCD: National Institute on Deafness and Other Communication Disorders
NIDCR: National Institute of Dental and Craniofacial Research
NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases
NIHES: National Institute of Environmental Health Sciences
NIGMS: National Institute of General Medical Sciences
NIMH: National Institute of Mental Health
NIMHD: National Institute on Minority Health and Health Disparities
NINDS: National Institute of Neurological Disorders and Stroke
NINR: National Institute of Nursing Research
NLM: National Library of Medicine

Join the private GBG Zoom Meeting:

<https://uso6web.zoom.us/j/81717200463?pwd=Ny40bFQGEH3nSNwt4LJpL4ouWFEWtX.1>

Meeting ID: 817 1720 0463

Passcode: 031056

